IT Versione italiana

up-dating events » New physiological treatment of vulvovaginal atrophy of menopause


Local administration of prasterone (DHEA): a new way to treat VVA and dispareunia

This symposium, sponsored by Endoceutics, took place during the 2015 ESG congress in Prague. It focused on the role and importance of DHEA in female sexual organ dysfunction during menopause, especially in vulvovaginal atrophy and dyspareunia. DHEA is a precursor of androgens and estrogens that occurs at the highest levels at the age of thirty and then decreases on average by 60 percent at menopause. DHEA substitution and routes of administration were the subject of the reports and the discussions that follow.




full talks

interviews



Cookies helps us to provide our services. Using these services , you agree to use of cookies on our part. OK